EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer

Tackhoon Kim iD, Byung-Sun Park, Soobeen Heo, Heeju Jeon, Jaeyeal Kim, Donghwa Kim, Sang Kook Lee, So-Youn Jung, Sun-Young Kong, Timothy Lu

eLife · 2025

DOI: 10.7554/elife.93921 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2025. Verfasst von Tackhoon Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Medicinal Materials Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Proto-Oncogene Proteins c-fyn, Jumonji Domain-Containing Histone Demethylases, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Institute of Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tyrosine kinases play a crucial role in cell proliferation and survival and are extensively investigated as targets for cancer treatment. However, the efficacy of most tyrosine kinase inhibitors (TKIs) in cancer therapy is limited due to resistance. In this study, we identify a synergistic combination therapy involving TKIs for the treatment of triple negative breast cancer. By employing pairwise tyrosine kinase knockout CRISPR screens, we identify FYN and KDM4 as critical targets whose inhibition enhances the effectiveness of TKIs, such as NVP-ADW742 (IGF-1R inhibitor), gefitinib (EGFR inhibitor), and imatinib (ABL inhibitor) both in vitro and in vivo. Mechanistically, treatment with TKIs upregulates the transcription of KDM4 , which in turn demethylates H3K9me3 at FYN enhancer for FYN transcription. This compensatory activation of FYN and KDM4 contributes to the resistance against TKIs. FYN expression is associated with therapy resistance and persistence by demonstrating its upregulation in various experimental models of drug-tolerant persisters and residual disease following targeted therapy, chemotherapy, and radiotherapy. Collectively, our study provides novel targets and mechanistic insights that can guide the development of effective combinatorial targeted therapies, thus maximizing the therapeutic benefits of TKIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsProto-Oncogene Proteins c-fynJumonji Domain-Containing Histone DemethylasesProtein Kinase InhibitorsAntineoplastic AgentsHumansAnimalsFemaleCell Line, TumorMiceDrug SynergismCRISPR-Cas SystemsDrug Resistance, Neoplasm

Stichwörter der Autor:innen

CRISPR screenbreast cancercancer biologygeneticsgenomicshistone demethylasehumantyrosine kinase

Substanzen

Proto-Oncogene Proteins c-fynFYN protein, humanJumonji Domain-Containing Histone DemethylasesProtein Kinase InhibitorsAntineoplastic Agents

Autor:innen und Institutionen

  • Medicinal Materials Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.
  • Department of Biological Sciences, Korea University, Seoul, Republic of Korea.
  • Division of Bio-Medical Science and Technology, Korea University of Science and Technology, Daejeon, Republic of Korea.
  • Research Lab of Electronics, Massachusetts Institute of Technology, Cambridge, United States.
  • Targeted Therapy Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, Republic of Korea.
  • College of Pharmacy, Natural Products Research Institute, Seoul National University, Seoul, Republic of Korea.

ORCID-Profile: Tackhoon Kim

Förderung

  • National Research Foundation of Korea
  • Korea Institute of Science and Technology

Zitieren

APA

Kim, T., Park, B. S., Heo, S., Jeon, H., Kim, J., Kim, D., Kook Lee, S., Jung, S. Y., Kong, S. Y., & Lu, T. (2025). Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer. eLife. https://doi.org/10.7554/elife.93921

Vancouver

Kim T, Park BS, Heo S, Jeon H, Kim J, Kim D, et al. Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer. eLife. 2025. doi:10.7554/elife.93921

BibTeX
@article{Kim2025,
  author = {Kim, Tackhoon and Park, Byung-Sun and Heo, Soobeen and Jeon, Heeju and Kim, Jaeyeal and Kim, Donghwa and Kook Lee, Sang and Jung, So-Youn and Kong, Sun-Young and Lu, Timothy},
  title = {Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer},
  journal = {eLife},
  year = {2025},
  doi = {10.7554/elife.93921}
}
Kostenlos starten →